Artios teams up with GSK to evaluate alnodesertib

UK based clinical-stage biotech Artios Pharma announced a clinical trial collaboration and supply agreement with UK pharma major GSK (LSE: GSK) to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez), GSK’s novel investigational B7-H3-targeting topoisomerase-1 (Topo-1) antibody-drug conjugate (ADC), in patients with gastrointestinal tumors.

“We’re excited to collaborate with GSK to investigate the potential of this combination strategy to provide meaningful benefit to patients with GI tumors,” said Mike Andriole, chief executive of Artios. “As we advance the development of alnodesertib in multiple solid tumors, this collaboration enables Artios to broaden our combinatorial strategy and unlock the full potential of exploiting replication stress biology in cancer,” he noted.